Your browser doesn't support javascript.
loading
Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.
Gao, Feng; Bonsignori, Mattia; Liao, Hua-Xin; Kumar, Amit; Xia, Shi-Mao; Lu, Xiaozhi; Cai, Fangping; Hwang, Kwan-Ki; Song, Hongshuo; Zhou, Tongqing; Lynch, Rebecca M; Alam, S Munir; Moody, M Anthony; Ferrari, Guido; Berrong, Mark; Kelsoe, Garnett; Shaw, George M; Hahn, Beatrice H; Montefiori, David C; Kamanga, Gift; Cohen, Myron S; Hraber, Peter; Kwong, Peter D; Korber, Bette T; Mascola, John R; Kepler, Thomas B; Haynes, Barton F.
Afiliação
  • Gao F; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA. Electronic address: fgao@duke.edu.
  • Bonsignori M; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Liao HX; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Kumar A; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Xia SM; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Lu X; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Cai F; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Hwang KK; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Song H; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Zhou T; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Lynch RM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Alam SM; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Moody MA; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Ferrari G; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Berrong M; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Kelsoe G; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Shaw GM; Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Hahn BH; Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Montefiori DC; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA.
  • Kamanga G; UNC Project, Lilongwe, Malawi; Departments of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Cohen MS; Departments of Medicine, Epidemiology and Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Hraber P; Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87544, USA.
  • Kwong PD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Korber BT; Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87544, USA.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Kepler TB; Department of Microbiology, Boston University, Boston, MA 02215, USA.
  • Haynes BF; Duke University Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham NC 27710, USA; The Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery at Duke University, Durham NC 27710, USA. Electronic address: barton.haynes@d
Cell ; 158(3): 481-91, 2014 Jul 31.
Article em En | MEDLINE | ID: mdl-25065977
ABSTRACT
Development of strategies for induction of HIV-1 broadly neutralizing antibodies (bnAbs) by vaccines is a priority. Determining the steps of bnAb induction in HIV-1-infected individuals who make bnAbs is a key strategy for immunogen design. Here, we study the B cell response in a bnAb-producing individual and report cooperation between two B cell lineages to drive bnAb development. We isolated a virus-neutralizing antibody lineage that targeted an envelope region (loop D) and selected virus escape mutants that resulted in both enhanced bnAb lineage envelope binding and escape mutant neutralization-traits associated with increased B cell antigen drive. Thus, in this individual, two B cell lineages cooperated to induce the development of bnAbs. Design of vaccine immunogens that simultaneously drive both helper and broadly neutralizing B cell lineages may be important for vaccine-induced recapitulation of events that transpire during the maturation of neutralizing antibodies in HIV-1-infected individuals.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Anticorpos Neutralizantes Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Anticorpos Neutralizantes Idioma: En Ano de publicação: 2014 Tipo de documento: Article